ArticleBioengineering (Basel, Switzerland)2025
AI-RiskX: An Explainable Deep Learning Approach for Identifying At-Risk Patients During Pandemics.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Energy Measures as Biomarkers of SARS-CoV-2 Variants and Receptors.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pandemics place extraordinary pressure on healthcare systems, particularly in identifying and prioritizing high-risk groups such as the elderly, pregnant women, and individuals with chronic diseases. Existing Artificial Intelligence models often fall short, focusing on single diseases, lacking interpretability, and overlooking patient-specific vulnerabilities. To address these gaps, we propose an Explainable Deep Learning approach for identifying at-risk patients during pandemics (AI-RiskX). AI-RiskX performs risk classification of patients diagnosed with COVID-19 or related infections to support timely intervention and resource allocation. Unlike previous models, AI-RiskX integrates five public datasets (asthma, diabetes, heart, kidney, and thyroid), employs the Synthetic Minority Over-sampling Technique (SMOTE) for class balancing, and uses a hybrid convolutional neural network-long short-term memory model (CNN-LSTM) for robust disease classification. SHAP (SHapley Additive exPlanations) enables both individual and population-level interpretability, while a post-prediction rule-based module stratifies patients by age and pregnancy status. Achieving 98.78% accuracy, AI-RiskX offers a scalable, interpretable solution for equitable classification and decision support in public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.